LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Олександр Войтко, Nikolay Conev, Igor Bondarenko, Stuart Spencer, Mingchao Xie, Stephanie Jones, April Franks, Yashaswi Shrestha, Luis Paz‐Ares